Latest Conference Articles

CheckMate 8HW data show ipilimumab plus nivolumab improved PFS vs nivolumab alone while maintaining HRQOL.

Durvalumab plus FLOT did not lead to differences in patient-reported outcomes vs placebo plus FLOT in resectable gastric/GEJ cancer.

Eileen M. O’Reilly, MD, discusses the rapidly evolving role of local therapy in the management of advanced/metastatic pancreatic cancer.

Benjamin A. Weinberg, MD, FACP, discusses preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC.

Invikafusp alfa produced responses as a single agent in antigen-rich gastrointestinal tumors, including metastatic colorectal cancer.

Irpagratinib combined with atezolizumab was effective and safe in both treatment-naive and ICI-exposed advanced HCC with FGF19 overexpression.

Certepetide plus gemcitabine and nab-paclitaxel was safe and effective in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Rachel Riechelmann, MD, PhD, discusses clinical guidance for the management of refractory carcinoid syndrome in functional GI neuroendocrine tumors.

A research fellow from Dana-Farber Cancer Institute shares post hoc findings from the phase 3 JAVELIN Renal 101 trial.

Ajai Chari, MD, expands on areas of uncertainty in multiple myeloma after his presentation at the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.

Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Selinexor improved PFS, TFST, TSST, and PFS2 in TP53 wild-type advanced/recurrent endometrial cancer.

Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.

Mirvetuximab soravtansine continues to show efficacy and safety in final analysis of the phase 2 PICCOLO study.

Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.

Rucaparib maintenance improved PFS in HRD-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.

Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.

Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.

BGB-16673 was safe and effective for the treatment of patients with relapsed/refractory Waldenström Macroglobulinemia.

Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.

A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.